- Event featuring renowned myelofibrosis expert
Dr. Ruben Mesa scheduled for
10:00 am ET on Wednesday, May
13th -
VANCOUVER, May 7, 2020 /CNW/ - Sierra Oncology, Inc.
(SRRA), a late-stage drug development company focused on the
registration and commercialization of momelotinib, a JAK1, JAK2
& ACVR1 inhibitor with a potentially differentiated therapeutic
profile for the treatment of myelofibrosis, today announced that it
will host an Analyst & Investor Call to discuss anemia and
transfusion dependency, two critical unmet medical needs in
treating patients with myelofibrosis, on Wednesday, May 13th at 10:00 am ET. The event will feature a
presentation by renowned myelofibrosis expert Dr. Ruben Mesa, Director of the Mays Cancer Center,
home to UT Health San Antonio MD Anderson Cancer Center.
"Cytopenias are very common in myelofibrosis, with anemia and
the resulting transfusion dependency being strongly associated with
poor prognosis and impaired survival in this disease," said Dr.
Mesa. "In clinical trials, momelotinib has consistently
demonstrated immediate and sustained anemia benefits that manifest
in an overall reduced transfusion burden, while sparing platelets
and achieving clinically comparable benefits on symptoms and
splenomegaly to that of the standard-of-care agent, ruxolitinib.
With treatments desperately lacking both for first line patients
with either severe anemia or transfusion dependency at
presentation, and for the largely cytopenic second line population,
momelotinib may offer a potentially important and broadly used new
therapeutic option for patients. As such advancing the MOMENTUM
Phase 3 trial, which is currently enrolling patients, is a high
priority for the MF clinical community."
Dr. Mesa's practice builds on his role as an international
expert on myeloproliferative neoplasms (MPNs), a group of bone
marrow disorders which include myelofibrosis. He has been involved
in MPN research for more than 20 years. He led the development of
National Comprehensive Cancer Network's panel guidelines, the first
U.S. guidelines on the diagnosis and treatment of myelofibrosis,
polycythemia vera and essential thrombocythemia. Dr. Mesa was
elected to sit on the National Board of Directors for the Leukemia
and Lymphoma Society and sits on the board of the MPN Education
Foundation. Dr. Mesa is an investigator in the MOMENTUM Phase 3
trial of momelotinib, which is intended to confirm the array of
clinical benefits previously described for the drug candidate.
Dr. Mesa and members of Sierra Oncology's senior management team
will be available to answer questions from analysts at the
conclusion of the event.
Analyst and Investor Event and Webcast Information
Date and Time: Wednesday, May
13th at 10:00 am
ET
Domestic (Toll Free- US): 1-877-407-4018
International (Toll): 1-201-689-8471
Conference ID: 13702348
Webcast Link:
https://viavid.webcasts.com/starthere.jsp?ei=1305667&tp_key=8595ee9eeb
Call registration is available through the Sierra Oncology
website at www.sierraoncology.com. An archive of the presentation
will be accessible after the event through the Sierra Oncology
website.
About Sierra Oncology
Sierra Oncology is a late stage drug development company focused
on achieving the successful registration and commercialization of
momelotinib, a potent, selective and orally-bioavailable JAK1, JAK2
& ACVR1 inhibitor with a targeted mechanism of action that
enables it to address all three key drivers of myelofibrosis.
Momelotinib's differentiated therapeutic profile encompasses robust
constitutional symptom improvements, a range of meaningful anemia
benefits, including eliminating or reducing the need for frequent
blood transfusions, and comparable spleen control to ruxolitinib.
More than 1,200 subjects have received momelotinib since clinical
studies began in 2009, including more than 820 patients treated for
myelofibrosis.
Sierra has launched MOMENTUM, a randomized double-blind Phase 3
clinical trial designed to enroll 180 myelofibrosis patients who
are symptomatic and anemic, and who have been treated previously
with a JAK inhibitor. The U.S. Food and Drug Administration has
granted Fast Track designation to momelotinib. Momelotinib is
protected by patents anticipated to provide potential exclusivity
to 2040 in the United States and
Europe (inclusive of potential
Patent Term Extension or Supplementary Protection Certificate).
For more information, please
visit www.sierraoncology.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, statements regarding Sierra Oncology's expectations
from current data, anticipated clinical development activities,
expected success of enrollment of MOMENTUM, and potential
benefits of momelotinib. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. These statements are based on management's current
expectations and beliefs and are subject to a number of risks,
uncertainties and assumptions that could cause actual results to
differ materially from those described in the forward-looking
statements. Such forward-looking statements are subject to risks
and uncertainties, including, among others, the risk that Sierra
Oncology's cash resources may be insufficient to fund its current
operating plans and it may be unable to raise additional capital
when needed, the risk that disruptions and impacts of COVID-19 will
be significant and lengthy, Sierra Oncology may be unable to
successfully develop and commercialize momelotinib,
momelotinib may not demonstrate safety and efficacy or
otherwise produce positive results, Sierra Oncology may experience
delays in the clinical development of momelotinib, Sierra Oncology
may be unable to acquire additional assets to build a pipeline of
additional product candidates, Sierra Oncology's third-party
manufacturers may cause its supply of materials to become limited
or interrupted or fail to be of satisfactory quantity or quality,
Sierra Oncology may be unable to obtain and enforce intellectual
property protection for its technologies and momelotinib and the
other factors described under the heading "Risk Factors" set forth
in Sierra Oncology's filings with the Securities and Exchange
Commission from time to time. Sierra Oncology undertakes no
obligation to update the forward-looking statements contained
herein or to reflect events or circumstances occurring after the
date hereof, other than as may be required by applicable
law.
View original
content:http://www.prnewswire.com/news-releases/sierra-oncology-to-hold-kol-call-to-discuss-anemia--transfusion-dependency-as-critical-unmet-needs-in-myelofibrosis-301054801.html
SOURCE Sierra Oncology